Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GTE-001 in Advanced Lung Adenocarcinoma
NCT06491225Phase 1Terminated
- Sponsor
- Grit Biotechnology
- Start
- Jul 2024
- Primary completion
- Aug 2024
- Modality
- Tumor-Infiltrating Lymphocytes (TILs)
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of GTE-001 in lung adenocarcinoma, sponsored by Grit Biotechnology. Primary endpoint: Objective Response Rate at 3 years. Started Jul 2024; status: terminated.
02
Drugs
GTE-001
03
Conditions
lung adenocarcinoma
Beyond the preview
Go deeper on NCT06491225.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06491225.